The described molecular mechanism suggests that the downregulation of miR-193b increases the expression of dimethylarginine dimethylaminohydrolase 1 (DDAH1), which negatively impacts the expression of the NOS inhibitor asymmetric dimethylarginine (ADMA), resulting in an increase in tumor severity by increasing proliferation and migration in breast cancer [97] (Figure 3A3, Table 2). Here, DDAH1 is linked to breast carcinoma.